An interventional study of tandard Treatment + Digital Monitoring (Intervention Group) and Standard Multidisciplinary Treatment (Control Group) in Chronic Pain, Multidisciplinary Biopsychosocial Program and Quality of Life, sponsored by Osijek University Hospital. Not yet recruiting at 1 site in Croatia. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-03-06.
Sponsored by Osijek University Hospital · Not applicable, Interventional, and Treatment
This randomized controlled study will evaluate the effectiveness of real-time digital intelligence in the treatment of chronic pain. A total of 80 adult patients enrolled in a four-week multidisciplinary chronic pain programme will be randomly assigned to either standard treatment alone or standard treatment supported by a smartwatch and a mobile application for real-time monitoring of pain intensity, analgesic use, physical activity, and heart rate.
Both groups will complete validated questionnaires assessing pain intensity, disability, quality of life, sleep, anxiety, depression, and treatment satisfaction at baseline, two weeks, and four weeks. The intervention group will additionally record daily pain scores and medication use via a mobile application and wear a smartwatch for continuous activity and heart rate monitoring.
The study aims to determine whether real-time digital monitoring and physician availability improve clinical outcomes compared with standard multidisciplinary care alone.
**Detailed Description**
This study is a prospective, randomized controlled trial designed to evaluate the added value of real-time digital intelligence in a structured, four-week multidisciplinary chronic pain programme.
Eligible adult patients with chronic pain who are enrolled in the programme will be randomly assigned (1:1) to either standard multidisciplinary treatment or standard treatment supplemented with digital monitoring tools. Randomisation will be performed using computer-generated allocation.
The control group will receive the usual four-week multidisciplinary intervention and complete validated outcome measures at baseline, week 2, and week 4. These measures will assess pain intensity, pain-related disability, quality of life, sleep quality, anxiety, depression, and treatment satisfaction.
The intervention group will receive the same multidisciplinary treatment and assessment schedule. In addition, participants will use a smartwatch to continuously monitor physical activity and heart rate and a mobile application to record daily pain intensity, timing of regular analgesic therapy, and use of rescue medication. Study questionnaires will also be completed through the mobile application. Physicians will have continuous access to patient-reported data during the study period.
The primary objective is to determine whether real-time digital monitoring improves clinical outcomes compared with standard multidisciplinary care alone. Secondary objectives include evaluating patient engagement, feasibility of implementation, and satisfaction with digitally supported pain management.
Exclusion criteria include refusal to participate and inability to use a smartphone.
2,930 studies on the registry are indexed under Chronic Pain; 701 are open to participants now.
This study's planned enrollment of 80 is above the median of 60 across 2,161 interventional studies indexed under Chronic Pain.
Browse Chronic Pain studies →Osijek University Hospital is the lead sponsor of 30 studies on the registry; 9 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Age 18-65 years Chronic low back pain significantly affecting disability and/or emotional distress
Exclusion Criteria:
Age \<18 or >65
The intervention group will receive the same multidisciplinary treatment and assessment schedule. In addition, participants will use a smartwatch to continuously monitor physical activity and heart rate and a mobile application to record daily pain intensity, timing of regular analgesic therapy, and use of rescue medication. Study questionnaires will also be completed through the mobile application. Physicians will have continuous access to patient-reported data during the study period.
Behavioral: tandard Treatment + Digital Monitoring (Intervention Group)
The control group will receive the usual four-week multidisciplinary intervention and complete validated outcome measures at baseline, week 2, and week 4. These measures will assess pain intensity, pain-related disability, quality of life, sleep quality, anxiety, depression, and treatment satisfaction.
Behavioral: Standard Multidisciplinary Treatment (Control Group)
The intervention group will receive the same multidisciplinary treatment and assessment schedule. Participants will use a smartwatch to continuously monitor physical activity and heart rate
The control group will receive the usual four-week multidisciplinary intervention and complete validated outcome measures at baseline, week 2, and week 4. These measures will assess pain intensity, pain-related disability, quality of life, sleep quality, anxiety, depression, and treatment satisfaction.
Change in pain intensity measured at baseline, Week 2, and Week 4 using the Numeric Rating Scale (0-10).
ain intensity is assessed at baseline, Week 2, and Week 4 using a self-reported 11-point Numeric Rating Scale (0 = no pain; 10 = worst imaginable pain). The outcome represents the change in pain intensity over time, with greater reductions indicating clinical improvement.
Time frame: aseline, Week 2, and Week 4
Change in the SF-36 Physical Functioning domain score from baseline to Week 2 and Week 4.
Health-related quality of life is assessed using the Croatian-validated Short Form-36 questionnaire. The outcome represents the change in the Physical Functioning domain score (range 0-100; higher scores indicate better functioning) measured at baseline, Week 2, and Week 4. Greater increases in score indicate clinical improvement.
Time frame: baseline, Week 2, and Week 4
Change in the SF-36 Physical Limitations domain score over time, measured at baseline, Week 2, and Week 4.
Health-related quality of life is assessed using the Croatian-validated Short Form-36 questionnaire. The outcome represents the change in the Physical Limitations domain score (range 0-100; higher scores indicate fewer physical limitations) measured at baseline, Week 2, and Week 4. Greater increases in score indicate clinical improvement.
Time frame: baseline, Week 2, and Week 4
Change in the SF-36 Emotional Limitations domain score over time, measured at baseline, Week 2, and Week 4.
Health-related quality of life is assessed using the Croatian-validated Short Form-36 questionnaire. The outcome represents the change in the Emotional Limitations domain score (range 0-100; higher scores indicate fewer emotional limitations) measured at baseline, Week 2, and Week 4. Greater increases in score indicate clinical improvement.
Time frame: baseline, Week 2, and Week 4
Change in the SF-36 Energy and Vitality domain score over time, measured at baseline, Week 2, and Week 4
Health-related quality of life is assessed using the Croatian-validated Short Form-36 questionnaire. The outcome represents the change in the Energy and Vitality domain score (range 0-100; higher scores indicate greater energy and vitality) measured at baseline, Week 2, and Week 4. Greater increases in score indicate clinical improvement.
Time frame: baseline, Week 2, and Week 4
Change in the SF-36 Psychological Health domain score over time, measured at baseline, Week 2, and Week 4.
Health-related quality of life is assessed using the Croatian-validated Short Form-36 questionnaire. The outcome represents the change in the Psychological Health domain score (range 0-100; higher scores indicate better psychological well-being) measured at baseline, Week 2, and Week 4. Greater increases in score indicate clinical improvement.
Time frame: baseline, Week 2, and Week 4
Change in the SF-36 Social Functioning domain score over time, measured at baseline, Week 2, and Week 4
Health-related quality of life is assessed using the Croatian-validated Short Form-36 questionnaire. The outcome represents the change in the Social Functioning domain score (range 0-100; higher scores indicate better social functioning) measured at baseline, Week 2, and Week 4. Greater increases in score indicate clinical improvement.
Time frame: baseline, Week 2, and Week 4
Change in the SF-36 Physical Pain domain score over time, measured at baseline, Week 2, and Week 4
Health-related quality of life is assessed using the Croatian-validated Short Form-36 questionnaire. The outcome represents the change in the Physical Pain domain score (range 0-100; higher scores indicate less pain) measured at baseline, Week 2, and Week 4. Greater increases in score indicate clinical improvement.
Time frame: baseline, Week 2, and Week 4
Change in the SF-36 General Health domain score from baseline to Week 2 and Week 4.
Health-related quality of life is assessed using the Croatian-validated Short Form-36 questionnaire. The outcome represents the change in the General Health domain score (range 0-100; higher scores indicate better perceived health) measured at baseline, Week 2, and Week 4. Greater increases in score indicate clinical improvement.
Time frame: baseline, Week 2, and Week 4
Change in Oswestry Disability Index (ODI) 2.1a total score from baseline to Week 2 and Week 4
Disability related to low back pain is assessed using the Croatian-validated version of the Oswestry Disability Index (ODI) 2.1a questionnaire. The outcome represents the change in the total ODI score (range 0-100; higher scores indicate greater disability) measured at baseline, Week 2, and Week 4. Greater decreases in score indicate clinical improvement.
Time frame: baseline, Week 2, and Week 4
Change in Depression score measured by the Depression Anxiety Stress Scales-21 (DASS-21) from baseline to Week 2 and Week 4
Symptoms of depression are assessed using the Croatian-validated version of the Depression Anxiety Stress Scales-21 (DASS-21). The outcome represents the change in the Depression subscale score measured at baseline, Week 2, and Week 4. Higher scores indicate more severe depressive symptoms, and greater decreases in score indicate clinical improvement.
Time frame: baseline to Week 2 and Week 4
Change in Anxiety score measured by the Depression Anxiety Stress Scales-21 (DASS-21) from baseline to Week 2 and Week 4
Symptoms of anxiety are assessed using the Croatian-validated version of the Depression Anxiety Stress Scales-21 (DASS-21). The outcome represents the change in the Anxiety subscale score measured at baseline, Week 2, and Week 4. Higher scores indicate more severe anxiety symptoms, and greater decreases in score indicate clinical improvement.
Time frame: baseline to Week 2 and Week 4
Change in Stress score measured by the Depression Anxiety Stress Scales-21 (DASS-21) from baseline to Week 2 and Week 4
Stress symptoms are assessed using the Croatian-validated version of the Depression Anxiety Stress Scales-21 (DASS-21). The outcome represents the change in the Stress subscale score measured at baseline, Week 2, and Week 4. Higher scores indicate more severe stress symptoms, and greater decreases in score indicate clinical improvement.
Time frame: baseline, Week 2, and Week 4
Change in Subjective Sleep Quality score measured by the Pittsburgh Sleep Quality Index (PSQI) from baseline to Week 2 and Week 4
Sleep quality is assessed using the Pittsburgh Sleep Quality Index (PSQI). The outcome represents the change in the Subjective Sleep Quality component score measured at baseline, Week 2, and Week 4. Higher scores indicate worse sleep quality, and greater decreases in score indicate clinical improvement.
Time frame: baseline to Week 2 and Week 4
Change in Sleep Latency score measured by the PSQI from baseline to Week 2 and Week 4
Sleep latency is assessed using the Pittsburgh Sleep Quality Index (PSQI). The outcome represents the change in the Sleep Latency component score measured at baseline, Week 2, and Week 4. Higher scores indicate longer time to fall asleep and worse sleep, and greater decreases indicate clinical improvement.
Time frame: baseline, Week 2, and Week 4.
Change in Sleep Duration score measured by the PSQI from baseline to Week 2 and Week 4
Sleep duration is assessed using the PSQI. The outcome represents the change in the Sleep Duration component score measured at baseline, Week 2, and Week 4. Higher scores indicate shorter sleep duration and worse sleep, and greater decreases indicate clinical improvement.
Time frame: baseline, Week 2, and Week 4
Change in Habitual Sleep Efficiency score measured by the PSQI from baseline to Week 2 and Week 4
Habitual Sleep Efficiency is assessed using the PSQI. The outcome represents the change in the Habitual Sleep Efficiency component score measured at baseline, Week 2, and Week 4. Higher scores indicate lower sleep efficiency and worse sleep, and greater decreases indicate clinical improvement.
Time frame: baseline, Week 2, and Week 4
Change in Sleep Disturbances score measured by the PSQI from baseline to Week 2 and Week 4
Sleep Disturbances are assessed using the PSQI. The outcome represents the change in the Sleep Disturbances component score measured at baseline, Week 2, and Week 4. Higher scores indicate more frequent disturbances and worse sleep, and greater decreases indicate clinical improvement.
Time frame: baseline, Week 2, and Week 4.
Change in Use of Sleeping Medication score measured by the PSQI from baseline to Week 2 and Week 4
Use of Sleeping Medication is assessed using the PSQI. The outcome represents the change in the Use of Sleeping Medication component score measured at baseline, Week 2, and Week 4. Higher scores indicate more frequent medication use, and greater decreases indicate clinical improvement.
Time frame: baseline, Week 2, and Week 4
Change in Daytime Dysfunction score measured by the PSQI from baseline to Week 2 and Week 4
Daytime Dysfunction is assessed using the PSQI. The outcome represents the change in the Daytime Dysfunction component score measured at baseline, Week 2, and Week 4. Higher scores indicate greater daytime impairment, and greater decreases indicate clinical improvement.
Time frame: baseline to Week 2 and Week 4
Physical activity (step count) measured by Apple Watch at baseline, Week 2, and Week 4
Physical activity (step count) is measured using the Apple Watch wearable device. The outcome represents the average daily step count recorded and summarized for the assessment periods at baseline, Week 2, and Week 4. Higher values indicate greater physical activity.
Time frame: baseline, Week 2, and Week 4
Sleep quality (Sleep Score) measured by Apple Watch at baseline, Week 2, and Week 4
Sleep quality (Sleep Score) is measured using sleep analysis data generated from sleep stage tracking recorded by the Apple Watch wearable device. The outcome represents the Sleep Score assessed and summarized at baseline, Week 2, and Week 4. Higher scores indicate better sleep quality.
Time frame: baseline, Week 2, and Week 4.
Change in PCS Rumination subscale score from baseline to Week 2 and Week 4
Pain rumination is assessed using the Rumination subscale of the Pain Catastrophizing Scale (PCS), a validated self-report questionnaire measuring repetitive negative focus on pain. The outcome represents the change in the PCS Rumination subscale score measured at baseline, Week 2, and Week 4. Higher scores indicate greater rumination, and greater decreases indicate clinical improvement.
Time frame: baseline, Week 2, and Week 4
Change in PCS Magnification subscale score from baseline to Week 2 and Week 4
Pain magnification is assessed using the Magnification subscale of the Pain Catastrophizing Scale (PCS). The outcome represents the change in the PCS Magnification subscale score measured at baseline, Week 2, and Week 4. Higher scores indicate greater magnification of pain, and greater decreases indicate clinical improvement.
Time frame: baseline, Week 2, and Week 4
Change in PCS Helplessness subscale score from baseline to Week 2 and Week 4
Pain-related helplessness is assessed using the Helplessness subscale of the Pain Catastrophizing Scale (PCS), a validated self-report questionnaire measuring perceived inability to cope with pain. The outcome represents the change in the PCS Helplessness subscale score measured at baseline, Week 2, and Week 4. Higher scores indicate greater helplessness, and greater decreases indicate clinical improvement.
Time frame: baseline, Week 2, and Week 4
Change in PCS total score from baseline to Week 2 and Week 4
Pain catastrophizing is assessed using the total score of the Pain Catastrophizing Scale (PCS). The outcome represents the change in the PCS total score measured at baseline, Week 2, and Week 4. Higher scores indicate greater pain catastrophizing, and greater decreases indicate clinical improvement.
Time frame: baseline, Week 2, and Week 4
Change in painDETECT questionnaire total score from baseline to Week 2 and Week 4
Neuropathic pain features are assessed using the painDETECT questionnaire, a validated self-report screening instrument designed to identify neuropathic pain components. The outcome represents the change in the painDETECT total score measured at baseline, Week 2, and Week 4. Higher scores indicate a greater likelihood of neuropathic pain, and greater decreases indicate clinical improvement.
Time frame: baseline, Week 2, and Week 4
Change in anxiety symptoms measured by the Hospital Anxiety and Depression Scale - Anxiety subscale (HADS-A).
Anxiety symptoms assessed using the Hospital Anxiety and Depression Scale (HADS). The anxiety subscale (HADS-A) consists of 7 items, each scored from 0 to 3, with total scores ranging from 0 to 21. Higher scores indicate greater anxiety symptom severity.
Time frame: Baseline, Week 2, and Week 4.
Change in depressive symptoms measured by the Hospital Anxiety and Depression Scale - Depression subscale (HADS-D).
Depressive symptoms assessed using the Hospital Anxiety and Depression Scale (HADS). The depression subscale (HADS-D) consists of 7 items, each scored from 0 to 3, with total scores ranging from 0 to 21. Higher scores indicate greater depressive symptom severity.
Time frame: Baseline, Week 2, and Week 4.
Change in neck-related disability measured by the Neck Disability Index (NDI).
Neck-related disability assessed using the Neck Disability Index (NDI), a 10-item patient- reported questionnaire evaluating the impact of neck pain on daily activities. Each item is scored from 0 to 5, with total scores ranging from 0 to 50. Higher scores indicate greater neck- related disability.
Time frame: Baseline, Week 2, and Week 4.
Beliefs about the necessity of medication measured by the Beliefs about Medicines Questionnaire - Specific Necessity subscale (BMQ-Specific Necessity) at Baseline, Week 2, and Week 4.
Beliefs about the personal necessity of prescribed medication assessed using the Beliefs about Medicines Questionnaire (BMQ) at Baseline, Week 2, and Week 4. The BMQ-Specific Necessity subscale consists of 5 items evaluating patients' beliefs about the need for their medication to maintain health and control illness. Each item is rated on a 5-point Likert scale (1 = strongly disagree to 5 = strongly agree), with total scores ranging from 5 to 25. Higher scores indicate stronger beliefs in the necessity of medication.
Time frame: Baseline, Week 2, and Week 4.
Concerns about medication measured by the Beliefs about Medicines Questionnaire - Specific Concerns subscale (BMQ-Specific Concerns) at Baseline, Week 2, and Week 4.
Concerns about prescribed medication assessed using the Beliefs about Medicines Questionnaire (BMQ) at Baseline, Week 2, and Week 4. The BMQ-Specific Concerns subscale consists of 5 items evaluating patients' worries about potential adverse effects and long-term consequences of medication. Each item is rated on a 5-point Likert scale (1 = strongly disagree to 5 = strongly agree), with total scores ranging from 5 to 25. Higher scores indicate greater concerns about medication.
Time frame: Baseline, Week 2, and Week 4.
Plan to share: No
This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Osijek University Hospital